

Shareholder Presentation

November 2015







DISCLAIMER

- This presentation has been prepared by BWX Limited ACN 169 015 838 (BWX) The information contained in this presentation is for information purposes only and has been prepared for use in conjunction with a verbal presentation and should be read in that context. This presentation is provided to you on the basis that you are a "sophisticated investor" (in accordance with subsection 708(8) or (10) of the Corporations Act 2001 (Cth) (Corporations Act)) or a "professional investor" (in accordance with subsection 708(11) of the Corporations Act), to whom his presentation has been prepared by BWX Limited ACN 169 015 838 (BWX). The information contained in this presentation is for information purposes only and has been a disclosure document is not required to be given under the Corporations Act.
- The information contained in this presentation is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. Please note that, in providing this presentation, BWX has not considered the objectives, financial position or needs of any particular recipient. BWX strongly suggests that investors consult a financial advisor prior to making an investment decision. This presentation is strictly confidential and is intended for the exclusive benefit of the institution to which it is presented. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of BWX. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of BWX, its related bodies corporate, shareholders or respective directors, officers, employees, agents or advisors, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence for any loss arising from the use of information contained in this presentation.
- This presentation may include "forward looking statements". Forward looking statements can generally be identified by the use of the words "anticipate", "believe", "expect", "project", "forecast", "estimate", "likely", "intend", "should", "could", "may", "target", "plan" "guidance" and other similar expressions. Indications of, and guidance on, future earning or dividends and financial position and performance are also forward looking statements. These forward looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of BWX and its officers, employees, agents or associates, that may cause actual results to differ materially from those expressed or implied in those statements. Actual results, performance or achievements may vary materially from any projections and forward looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward looking statements and BWX assumes no obligation to update that information.
- This presentation is not, and does not constitute, an offer to sell or the solicitation, invitation or recommendation to purchase any securities and neither this presentation nor anything contained in it forms the basis of any contract or commitment.
- This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The securities of BWX have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and any other applicable securities laws or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

OVERVIEW

ASX listed, BWX Limited is a vertically integrated developer, manufacturer, distributor and marketer of branded skin and hair care products with an emphasis on the 'Natural' segment of the beauty and personal care market.

The company owns, produces, and distributes under the Sukin, DermaSukin, Uspa, Edward Beale, and Renew Skincare brands.







COMPANY HIGHLIGHTS

Market leading brand – Sukin

Australia's No.1 selling 'natural' skin care brand in pharmacies
 Cyling is Australia's No.2 calling skin care brand in the pharmacies

BWX developed and manufactured Sukin products since 2007

- Sukin is Australia's No.2 selling skin care brand in the pharmacy channel
- Fastest growing brand by revenue of the top 5 skin care brands sold in Australian pharmacies¹

Strong Business Model

- BWX purchased Sukin in June 2015
 BWX owns the IP for the formulations of Sukin products and its other brands
 BWX operates from a purpose built manufacturing facility which it leases in
 - BWX operates from a purpose built manufacturing facility which it leases in Dandenong South, Victoria.
 - Integration and control of the production cycle provides cost efficiencies and scalability
 - Utilisation of independent domestic and international distributors provides a broad sales platform with low overheads

Substantial growth opportunities

- The 'Natural' segment of the skin care market grew 29 2015
- Sukin's total revenue is forecast to grow 26% in FY16
- Sukin's export revenue is forecast to grow 37% in FY1
- Sukin's products currently account for only 3.6% of Australian skin care pharmacy sales





COMPANY HIGHLIGHTS

New Product Development Capability

- Ability to respond rapidly to market trends by developing new products and brands
- Owner of a large formulation database which can be utilised to develop new products
- Launched Sukin Super Greens range in February 2015 which had achieved
 \$1 million in sales by June 2015

Experienced Board, management and personnel

- Strong board with complementary skill sets
- Experienced management
- Highly qualified and experienced new product development team

Attractive Financial Profile

- BWX pro-forma Revenue of \$45.1m in FY15 is forecast to increase by 11.1% to \$50.1m in FY16
- BWX pro-forma EBITDA of \$14.8m in FY15 is forecast to increase by 18.2% to \$17.5m in FY16
- BWX pro-forma NPAT of \$9.6m in FY15 is forecast to increase by 15.6% to \$11.1m in FY16
- BWX pro-forma gross margins in FY15 of 56.8% are forecast to increase to 58.7% in FY16
- Low debt and capital light operating model²

Dividends

Target dividend payout ratio of 35% to 50% FY16 forecast ¹

¹ Subject to financial conditions the BWX board intends to pay a final full year FY16 dividend.






GLOBAL AND DOMESTIC BEAUTY AND PERSONAL CARE MARKET

BWX operates in the beauty and personal care market in Australia and internationally

- BWX and its flagship brand Sukin operate predominantly in the skin care segment of the broader beauty and personal care market.
- In 2014 the global beauty and personal care market generated sales of approximately USD\$465 billion.
- The Australian beauty and personal care market generated sales of approximately A\$6.7 billion in 2014 of which skin care products accounted for 25% or \$1.67 billion.

Australian Beauty and Personal Care Market 2014 by Segment





Euromonitor International 2015



SKIN CARE MARKET AUSTRALIA PHARMACY CHANNEL

BWX's flagship brand Sukin operates in the skin care segment of the beauty and personal care market

- The majority of Sukin products are sold through pharmacies.
- Australian consumers spent A\$5.6 billion on nonprescription over the counter products in pharmacies in FY15, growing at 12.7% on a moving annual total basis.
- Sales of skin care products in Australian pharmacies for the 12 months ending June 2015 were A\$649 million. This result was up by 13.6% from the previous corresponding 12-month period when sales of A\$571 million were recorded.
- The broader Australian skin care market is projected to grow by 4.1% in total between 2014 and 2019.



'NATURAL' SKIN CARE MARKET SEGMENT

The Sukin brand targets the 'natural' segment of the beauty and personal care market

- The 'natural' skin care segment outperformed the broader skin care market with year on year growth of 35% in the 12 months to June 2015.
- According to Euromonitor International: "Sustainable and ethical aspects of beauty and personal care will be a key focus for manufacturers over the forecast period [2014-19] as they have become increasingly influential in consumers' purchasing decisions."
- BWX's management believes that the growing demand for 'natural' beauty and personal care products is driven by mounting public concerns for health and safety and increasing "green" consciousness and a growing awareness of the potential hazards of synthetic chemicals.












BWX **SUKIN BRAND**



SUKIN KEY HIGHLIGHTS





SUKIN COMPETITIVE LANDSCAPE

Sukin operates in the 'natural' skin care market in Australia

- Sukin is the number 1 'natural' skin care brand and the number 2 selling skin care brand overall in Australian pharmacies.
- The Sukin brand is targeted at the top end of the mass market segment of the broader skin care market known as Masstige.
- Sukin's average per unit price of \$11.30 aligns with Sukin's strategy of being perceived by consumers as a high end brand while remaining competitively priced and affordable.

"Skincare that doesn't cost the earth"

Australian Pharmacy Skin Care Sales June 2015

Brand	Val Sales ('000)	Unit Sales ('000)	Average \$A Price Per Unit
xxxxxxxx	\$25,826.5	3,626.3	\$7.12
Sukin	\$23,777.8	2,104.0	\$11.30
xxxxxxxx	\$21,732.5	1,079.8	\$20.13
xxxxxxxx	\$20,545.7	1,406.9	\$14.60
xxxxxxxx	\$18,538.6	952.8	\$19.46
xxxxxxxx	\$17,221.5	1,604.4	\$10.73
XXXXXXXX	\$15,521.6	1,114.0	\$13.93
xxxxxxxx	\$11,885.3	326.8	\$36.36
XXXXXXXX	\$10,546.3	2,411.5	\$4.37
xxxxxxxx	\$9,334.2	933.3	\$10.00

Source: AC Nielsen June 2015





SUKIN SALES GROWTH

Number one 'natural' skin care brand in Australian **Pharmacies**

- Fastest growing brand by revenue of the top 5 skin care brands sold in Australian pharmacies in the 12 months to June 2015.
- Sukin total annual skin care sales in pharmacies were A\$23.7 million which represented a growth rate of 35%.
- Sales of skin care products in Australian pharmacies grew by 13.6% to A\$649 million over the previous corresponding 12-month period when sales of A\$571 million were recorded.
- Sales of 'natural' skin care brands within pharmacies in the twelve months to June 2015 experienced growth of 29%.





SUKIN DISTRIBUTION - DOMESTIC

BWX utilises independent distributors to sell the Sukin products

- BWX utilises a wholesale distributor model to sell its products into pharmacies, health food stores and specialty stores.
- BWX also sells Sukin products direct to Priceline.
- BWX engages directly with the larger pharmacy banner groups such as Chemist Warehouse, Priceline and Terry White.
- Each Australian State based distributor has a sales team that drives demand for Sukin products.





SUKIN DOMESTIC GROWTH OPPORTUNITIES

Sukin's market leading performance will be maintained

- During FY15 Sukin significantly outperformed the broader skin care market within Australian pharmacies.
- Opportunity for further growth as Sukin accounted for 13% of the top 10 brands and 3.6% of the overall skin care sales in pharmacies in the 12 months to June 2015.
- Through brand extensions and new product development, BWX anticipates that it will continue to grow sales through the pharmacy channel.
- BWX's digital marketing campaign for Sukin is focused on reinforcing key brand messages to drive consumers demand.
- eCommerce enabled through www.sukinorganics.com where the majority of Sukin products are available for delivery within Australia.



Bianca Cheah Brand Ambassador



SUKIN **EXPORT OPPORTUNITIES**

Export markets represent a strong growth opportunity for the Sukin brand

- FY15 export sales of \$4.6m are forecast to increase by 37% to \$6.3m in FY16.
- The largest export markets in FY15 were New Zealand, US, Canada, Singapore and the UK.
- Products exported through a variety of different distribution channels.
- BWX management intends to expand Sukin's presence and penetration in various high growth export markets.
- The Chinese market will be the primary focus for growth in 2016





NEW PRODUCT DEVELOPMENT

BWX has the in-house capability to rapidly develop and commercialise new products in response to consumer trends

- BWX's management has two decades of experience developing and commercialising beauty and personal care products.
- BWX have the facilities and expertise to develop new products from conception through to shelf readiness.
- BWX has a database of proprietary formulations.
- In February 2015 BWX launched the **Sukin Super** Greens range which achieved sales of ~\$1m to June 2015



BWX DEVELOPMENT & PRODUCTION CAPABILITIES

BWX's products are produced at its purpose built and leased production facility

- BWX controls the production cycle for its products.
- The production facility is scalable to meet increased demand.
- The BWX production facility is ISO 22217:2006 'Guidelines on Good Manufacturing Practices (GMP)' certified for the manufacturing beauty and personal care products.
- Full R&D and new product development capability.



COMPLEMENTARY BRANDS

In addition to Sukin, BWX owns a range of complementary skin and hair care brands

USPQ

- Uspa is a premium range of skin care and hair care products formulated using essential oils and herbal extracts
- Uspa operates its own signature day spa and retail outlet which trades as the "Immersion Day Spa" in Brighton, Victoria.
- Uspa products are distributed in the Australian market to day spas and beauty salons through a network of State based distributors.
- Uspa is exported to USA, Singapore, New Zealand, Denmark, Netherlands, Malaysia, Taiwan, Japan, and Australia.
- There is substantial opportunities for growth both domestically and internationally





COMPLEMENTARY BRANDS



Natural Skin Care Brand for Sensitive Skin



Natural skin care range formulated for consumers with sensitive skin.



Natural Skin Care Brand



Face, body and hair care products produced using rose hip oil.



Premium Hair Care Range



Salon and retail range of hair care products.



THIRD PARTY MANUFACTURING

BWX provides product development and manufacturing services to select third party brands and customers



- BWX's strategy is to focus on developing its own brands.
- Revenue from third party manufacturing is anticipated to be diluted from approximately 32% in FY15 to 24.5% in FY16.
- Despite this strategic direction BWX intends to continue providing manufacturing services to select clients.
- The benefits to BWX of producing for external brands include large volume sales, scale of purchasing and potential acquisition opportunities.
- The demand for BWX's manufacturing services is driven by:
 - customers seeking Australian made products;
 - the integrity, traceability and safety of ingredients;
 - standards and certifications around the manufacturing process; and
 - speed to market.



ACQUISITION OPPORTUNITIES

BWX is well positioned as an acquirer of successful scalable brands and companies in the Australian beauty and personal care market



- The Australian beauty and personal care market includes a range of large multinational brands such as Nivea. L'Oreal and Garnier.
- Opportunities exist for brands such as Sukin to exploit undeveloped growth segments of the market.
- Many of these companies/brands in the Australian market have some or all of the following attributes:
 - rely on third party service providers for R&D and production capabilities;
 - limited warehouse and logistics capacity;
 - yet to access large distribution channels; and
 - insufficient capital and human resources to manage sustained growth.





BOARD



Denis Shelley Chairman

Experienced marketing executive with more than 30 years in a range of brands, FMCG and manufacturing.

Broad industry background encompassing health and beauty, personal care, intimate apparel, household products and pharmaceuticals.

Past roles include Group Chairman of Sara Lee Australia, CEO Sara Lee South Africa, CEO Sara Lee Household & Body Care Australia, Group Marketing director Reckitt & Colman South Africa, President of Nutrimetics Australia.



John Humble Chief Executive Officer and Managing Director

More than 20 years' experience in formulating, developing and producing personal care products.

Original founder of Leisure and Hospitality Services Pty Ltd (now merged into BWX Ltd) in 1993.

Instrumental in positioning BWX in the 'natural' personal care space.

Worked with Sukin in developing its IP/formulations since 2007.



Aaron Finlay Finance Director

More than 20 years experience as a chartered accountant and company secretary.

Has extensive public company experience in executive and director roles for ASX listed companies, including Mayne Pharma Group Limited (an ASX top 200 company), where Mr Finlay was instrumental in the acquisition of Mayne Pharmaceuticals International in 2009.

Also held roles as Australian CFO of INVESCO and Head of Group Tax & Treasury for INVESCO's global operations in London.



Craig Bottomley Independent Non-Executive Director

More than 20 years' experience establishing and developing commercial ventures in manufacturing and import/export. He has developed national and international sales channels for a number of local and domestic products.

One of the founders of Halcygen Pharmaceuticals Ltd working as COO and Executive Director from 2005 to 2010. Instrumental in acquiring Mayne Pharmaceuticals International in 2009, now Mayne Pharma Group Limited.



Ian Campbell Independent NonExecutive Director

Over 30 years of senior management and operational experience in manufacturing, sales and marketing, brand management, mergers and acquisitions, industrial relations and OH&S.

Currently a director of ASX listed Mirrabooka Investments Ltd.

14 years as Managing Director of ASX 200 GUD Holdings Ltd.

10 years with Pacific Dunlop Cables Group, the last six as Managing Director.

Financial Information



BWX FINANCIAL INFORMATION HISTORICAL AND FORECAST

Consolidated income Statement		Pro forma	historical			Forecast	
		6 months			6 mo	onths	
\$m	30-Jun-14	31-Dec-14	30-Jun-15	FY15	31-Dec-15	30-Jun-16	FY16
Revenue	16.7	22.0	23.1	45.1	24.7	25.4	50.1
Cost of sales	-7.8	-9.9	-9.6	-19.5	-9.8	-10.3	-20.1
Gross profit	8.9	12.1	13.5	25.6	14.9	15.1	30.0
Operating Costs	-4.3	-5.7	-5.1	-10.8	-6.3	-6.2	-12.5
EBITDA normalised	4.6	6.4	8.4	14.8	8.6	8.9	17.5
Acquisition and restructuring costs	-4.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	0.6	6.4	8.4	14.8	8.6	8.9	17.5
Depreciation and amortisation	-0.2	-0.2	-0.3	-0.5	-0.4	-0.4	-0.8
EBIT	0.4	6.2	8.1	14.3	8.2	8.5	16.7
Interest	-0.5	-0.5	-0.7	-1.2	-0.3	-0.1	-0.4
Profit before tax	-0.1	5.7	7.4	13.1	7.9	8.4	16.3
Income tax expense	-1.0	-1.8	-1.7	-3.5	-2.5	-2.7	-5.2
NPAT	-1.1	3.9	5.7	9.6	5.4	5.7	11.1



BWX FINANCIAL INFORMATION

FY15 AND FY16 COMPARISON OF SELECTED FINANCIAL INFORMATION

	Pro forma historical	Forecast	
\$m	FY15	FY16	Change
Revenue	45.1	50.1	11.1%
Cost of sales	-19.5	-20.1	3.1%
Gross profit	25.6	30.0	17.2%
Costs	-10.8	-12.5	15.7%
EBITDA normalised	14.8	17.5	18.2%
Acquisition and restructing costs	0.0	0.0	0.0%
EBITDA	14.8	17.5	18.2%
Depreciation and amortisation	-0.5	-0.8	60.0%
EBIT	14.3	16.7	16.8%
Interest	-1.2	-0.4	-66.7%
Profit before tax	13.1	16.3	24.4%
Income tax expense	-3.5	-5.2	48.6%
NPAT	9.6	11.1	15.6%
Revenue growth on pcp	n/a	11.2%	n/a
Gross margin	56.7%	59.9%	310 bpts
EBITDA normalised margin	32.8%	34.9%	210 bpts
EBITDA margin	32.8%	34.9%	210 bpts
EBIT margin	31.7%	33.3%	160 bpts
NPAT margin	21.3%	22.2%	90 bpts



BWX FINANCIAL INFORMATION BALANCE SHEET AS AT 30 JUNE 2015

	Statutory	Impact of Offer	Pro forma
Current assets			
Cash and cash equivalents	3.1	1.2	4.3
Trade and other receivables	7.4		7.4
Inventory	6.6		6.6
Other assets	-		-
Total current assets	17.1	1.2	18.3
Non-current assets	-		-
Property, plant and equipment	2.3		2.3
Intangible assets	70.1		70.1
Deferred tax assets	0.5		0.5
Total non-current assets	72.9		72.9
Total assets	90.0	1.2	91.2
Current liabilities	-		-
Trade and other payables	6.0		6.0
Borrowings	16.9	(7.3)	9.6
Income tax payable	-		-
Provisions	0.4		0.4
Total current liabilities	23.3	(7.3)	16.0
Non-current liabilities	-		-
Borrowings	10.1	(10.0)	0.1
Provisions	0.2		0.2
Total non-current liabilities	10.3	(10.0)	0.3
Total liabilities	33.6	(17.3)	16.3
Net assets	56.4	18.5	74.9

^{* \$18.5}m is net of \$1.5m to get to the \$20m Company raising





CORPORATE STRUCTURE

Key Statistics	
Shares on Issue	90.6m
Indicative market capitalisation at \$2.70 per share	\$244.6m
Estimated net debt	\$0.5m
Indicative enterprise value	\$245.1m

Of the shares currently on issue, 13,886,398 or 15.3% of the issued capital are on issue to the Board and are subject to voluntary escrow until 11 Nov 2016.

Of the shares currently on issue, 2,050,000 have been issued in accordance with the Company's employee loan plan and remain subject to performance milestones.

The Company has 5,940,000 options on issue over fully paid ordinary shares in the Company with an exercise price of \$2.00, an expiry date of 30 September 2018 and remain subject to performance milestones

BWX has an undrawn \$15m debt facility which may be used to fund or part fund future acquisitions.





COMPANY SUMMARY

- Market Leading Pharmacy Brand Sukin
- Positive 'Natural' skin care market dynamics
- Vertically integrated business manufacturing own brands
- Strong Business Model
- Multiple Growth Opportunities
- New Product Development Capability
- **Experienced Management**
- Potential Growth through Acquisitions
- **Attractive Financials**
- Dividends





Contact: Mr John Humble

Chief Executive Officer and Managing Director

jhumble@bwxltd.com

+61 3 8785 6300

